Next Article in Journal
Serological Detection of SARS-CoV-2 Antibodies in Naturally-Infected Mink and Other Experimentally-Infected Animals
Next Article in Special Issue
Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus
Previous Article in Journal
Monitoring SARS-CoV-2 Populations in Wastewater by Amplicon Sequencing and Using the Novel Program SAM Refiner
Previous Article in Special Issue
What Binds Cationic Photosensitizers Better: Brownian Dynamics Reveals Key Interaction Sites on Spike Proteins of SARS-CoV, MERS-CoV, and SARS-CoV-2
 
 
viruses-logo
Article Menu

Article Menu

Article

SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic

1
Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 127994 Moscow, Russia
2
Saint Petersburg Pasteur Institute, 197101 St. Petersburg, Russia
3
Rospotrebnadzor Administration in Moscow, 129626 Moscow, Russia
4
Rospotrebnadzor Administration in the Kaliningrad Region, 236040 Kaliningrad, Russia
5
Irkutsk Research Anti-Plague Institute, 664047 Irkutsk, Russia
6
Rospotrebnadzor Administration in St. Petersburg, 191025 St. Petersburg, Russia
7
Russian Research Anti-Plague Institute “Microbe”, 410005 Saratov, Russia
8
Center for Hygiene and Epidemiology of the Vladimir Region, 600005 Vladimir, Russia
9
Rospotrebnadzor Administration in the Chelyabinsk Region, 454091 Chelyabinsk, Russia
10
Rospotrebnadzor Administration in the Krasnoyarsk Territory, 660049 Krasnoyarsk, Russia
11
Rospotrebnadzor Administration in the Primorsky Krai, 690950 Vladivostok, Russia
12
Nizhny Novgorod I. N. Blokhina Research Institute of Epidemiology and Microbiology, 603950 Nizhny Novgorod, Russia
13
Rospotrebnadzor Administration in the Leningrad Region, 192029 St. Petersburg, Russia
14
Rospotrebnadzor Administration in the Stavropol Territory, 355008 Stavropol, Russia
15
Rospotrebnadzor Administration in the Sverdlovsk Region, 620078 Yekaterinburg, Russia
16
G. N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, 125212 Moscow, Russia
17
Rospotrebnadzor Administration in the Amur Region, 675002 Blagoveshchensk, Russia
18
Rospotrebnadzor Administration in the Tula Region, 300045 Tula, Russia
19
Rospotrebnadzor Administration in the Murmansk Region, 183038 Murmansk, Russia
20
Rospotrebnadzor Administration in the Moscow Region, 141014 Mytishchi, Moscow Region, Russia
21
Rostov-on-Don Research Anti-Plague Institute, 344000 Rostov-on-Don, Russia
22
Rospotrebnadzor Administration for the Astrakhan Region, 414057 Astrakhan, Russia
23
Rospotrebnadzor Administration in the Belgorod Region, 308023 Belgorod, Russia
24
Rospotrebnadzor Administration in the Krasnodar Territory, 350000 Krasnodar, Russia
25
Rospotrebnadzor Administration in the Republic of Tatarstan, 420111 Kazan, Russia
26
Rospotrebnadzor Administration in the Republic of Crimea, 295034 Simferopol, Russia
27
Rospotrebnadzor Administration in the Novosibirsk Region, 630132 Novosibirsk, Russia
28
Tyumen Research Institute of Regional Infectious Pathology, 625026 Tyumen, Russia
29
Khabarovsk Research Institute of Epidemiology and Microbiology, 680000 Khabarovsk, Russia
*
Author to whom correspondence should be addressed.
Academic Editors: Larisa Rudenko and Irina Isakova-Sivak
Viruses 2021, 13(8), 1648; https://doi.org/10.3390/v13081648
Received: 29 June 2021 / Revised: 11 August 2021 / Accepted: 11 August 2021 / Published: 19 August 2021
(This article belongs to the Special Issue State-of-the-Art Respiratory Viruses Research in Russia)
The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the “ELISA anti-SARS-CoV-2 IgG” reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer’s instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1–17, 18–29, 30–39, 40–49, 59–59, 60–69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8–23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1–31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8–21.1) to 18.0% (IQR: 13.4–22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1–94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity. View Full-Text
Keywords: SARS-CoV-2; COVID-19; herd immunity; asymptomatic form; Russia; population SARS-CoV-2; COVID-19; herd immunity; asymptomatic form; Russia; population
Show Figures

Figure 1

MDPI and ACS Style

Popova, A.Y.; Smirnov, V.S.; Andreeva, E.E.; Babura, E.A.; Balakhonov, S.V.; Bashketova, N.S.; Bugorkova, S.A.; Bulanov, M.V.; Valeullina, N.N.; Vetrov, V.V.; Goryaev, D.V.; Detkovskaya, T.N.; Ezhlova, E.B.; Zaitseva, N.N.; Istorik, O.A.; Kovalchuk, I.V.; Kozlovskikh, D.N.; Kombarova, S.Y.; Kurganova, O.P.; Lomovtsev, A.E.; Lukicheva, L.A.; Lyalina, L.V.; Melnikova, A.A.; Mikailova, O.M.; Noskov, A.K.; Noskova, L.N.; Oglezneva, E.E.; Osmolovskaya, T.P.; Patyashina, M.A.; Penkovskaya, N.A.; Samoilova, L.V.; Stepanova, T.F.; Trotsenko, O.E.; Totolian, A.A. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. Viruses 2021, 13, 1648. https://doi.org/10.3390/v13081648

AMA Style

Popova AY, Smirnov VS, Andreeva EE, Babura EA, Balakhonov SV, Bashketova NS, Bugorkova SA, Bulanov MV, Valeullina NN, Vetrov VV, Goryaev DV, Detkovskaya TN, Ezhlova EB, Zaitseva NN, Istorik OA, Kovalchuk IV, Kozlovskikh DN, Kombarova SY, Kurganova OP, Lomovtsev AE, Lukicheva LA, Lyalina LV, Melnikova AA, Mikailova OM, Noskov AK, Noskova LN, Oglezneva EE, Osmolovskaya TP, Patyashina MA, Penkovskaya NA, Samoilova LV, Stepanova TF, Trotsenko OE, Totolian AA. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. Viruses. 2021; 13(8):1648. https://doi.org/10.3390/v13081648

Chicago/Turabian Style

Popova, Anna Y., Viacheslav S. Smirnov, Elena E. Andreeva, Elena A. Babura, Sergey V. Balakhonov, Natalia S. Bashketova, Svetlana A. Bugorkova, Maxim V. Bulanov, Natalia. N. Valeullina, Viacheslav. V. Vetrov, Dmitriy. V. Goryaev, Tatyana N. Detkovskaya, Elena B. Ezhlova, Natalia N. Zaitseva, Olga A. Istorik, Irina. V. Kovalchuk, Dmitriy N. Kozlovskikh, Svetlana Y. Kombarova, Olga. P. Kurganova, Alexander. E. Lomovtsev, Lena A. Lukicheva, Ludmila V. Lyalina, Albina. A. Melnikova, Olga M. Mikailova, Alexei K. Noskov, Ludmila N. Noskova, Elena E. Oglezneva, Tatyana P. Osmolovskaya, Marina A. Patyashina, Natalia A. Penkovskaya, Lada V. Samoilova, Tatyana F. Stepanova, Olga E. Trotsenko, and Areg A. Totolian. 2021. "SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic" Viruses 13, no. 8: 1648. https://doi.org/10.3390/v13081648

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop